Intrahepatic Cholestasis of Pregnancy (ICP)
ICP is a liver condition that occurs during pregnancy. In ICP, the normal flow of bile is reduced, which causes bile to build up in the liver and bile acids to leak into the bloodstream. The main symptom of ICP is extreme itching in the palms of the hands and soles of the feet.
Quick Answer
What it is
ICP is a liver condition that occurs during pregnancy. In ICP, the normal flow of bile is reduced, which causes bile to build up in the liver and bile acids to leak into the bloodstream.
Key findings
- Grade N/A: Cholestasis (S-adenosylmethionine)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts
Quick Facts: Intrahepatic Cholestasis of Pregnancy (ICP)
- Supplements Studied:1
- Research Trials:1
- Total Participants:2,085
Evidence-Based Protocol
Supplement stack ranked by research quality
Primary Stack (Tier 1)
Supports liver methylation and bile acid metabolism; may reduce symptoms and improve liver function
Primary treatment; reduces bile acid levels and improves liver function (prescription)
Supporting Stack (Tier 2)
May be depleted in cholestasis due to fat malabsorption; supports clotting and fetal bone development
Absorption may be impaired in cholestasis; supports maternal and fetal bone health
Fat-soluble vitamin that may be depleted in cholestasis; antioxidant protection
Supports fetal development; may have anti-inflammatory effects
How It Works
Intrahepatic Cholestasis of Pregnancy (ICP) is a liver condition that occurs in the third trimester, causing intense itching (especially on the palms and soles) due to elevated bile acids in the blood. ICP affects about 1% of pregnancies and is associated with increased risks of preterm birth, fetal distress, and stillbirth if not managed. The condition resolves after delivery but may recur in future pregnancies.
CRITICAL: ICP requires medical management and close monitoring. The primary treatment is ursodeoxycholic acid (UDCA), a prescription medication that reduces bile acid levels and improves outcomes. Fetal monitoring (non-stress tests, sometimes biophysical profiles) is essential, and early delivery (typically 36-37 weeks) is often recommended depending on bile acid levels and other factors. These supplements may provide additional support but DO NOT replace UDCA therapy or obstetric monitoring. Inform your obstetrician about all symptoms - severe itching should prompt bile acid testing.
* S-Adenosylmethionine (SAMe) supports liver methylation pathways involved in bile acid metabolism. Meta-analyses show SAMe can reduce symptoms (itching, liver enzymes) in ICP, sometimes used in combination with UDCA.
* Ursodeoxycholic Acid (UDCA) is the primary treatment (prescription medication included here for completeness). It's a bile acid that reduces toxic bile acid levels and has been shown to improve maternal symptoms and possibly fetal outcomes.
* Vitamin K may be depleted in cholestasis due to reduced bile salts impairing fat absorption. Supplementation is important to prevent bleeding complications in mother and baby.
* Vitamin D absorption may also be impaired. Maintaining adequate levels supports maternal and fetal bone health.
* Vitamin E is another fat-soluble vitamin that may be affected by cholestasis.
* Omega-3 Fatty Acids support fetal brain and eye development and may have anti-inflammatory effects.
Expected timeline: SAMe effects may be noticed within 2-3 weeks. UDCA typically improves itching and bile acids within 1-2 weeks. ICP resolves quickly after delivery.
Detailed Outcomes
Research Citations (23)
Related Conditions
Parkinson's Disease
1 shared supplement · 18 outcomes
Parkinson’s disease is a neurodegenerative disease caused by progressive loss of dopamine-producing neurons in the brain. Symptoms are mild at first, but progress over time, leading to impaired movement as well as other neurocognitive and psychiatric symptoms like depression, dementia, bowel and bladder problems, and difficulty sleeping.
Osteoarthritis (OA)
1 shared supplement · 116 outcomes
Osteoarthritis (OA) is a joint disease involving cartilage degradation. It’s not clear what exactly causes OA, but some risk factors include joint injury, overweight or obesity, aging, misaligned joints, and family history. Lots of supplements have been studied in people with OA, as have lifestyle interventions including weight loss and exercise.
Nonalcoholic Fatty Liver Disease (NAFLD)
1 shared supplement · 221 outcomes
Non-alcoholic fatty liver disease (NAFLD) is a condition in which excessive fat (more than 5% of liver weight) accumulates in the liver due to causes unrelated to alcohol.
Metabolic Health
1 shared supplement · 975 outcomes
Research on metabolism, blood glucose regulation, insulin sensitivity, and metabolic syndrome.
Hepatitis C
1 shared supplement · 13 outcomes
Hepatitis C (HCV) is a virus that is transmitted through blood, with contaminated needles being a common source of infection. Chronic infection with HCV can lead to liver cirrhosis and liver cancer.
1 shared supplement · outcomes
General Cancer Care and Prevention
1 shared supplement · 50 outcomes
Cancer is a group of diseases in which abnormal cells divide out of control and can invade other tissues. Cancer care and prevention refers to treatments to try to manage and cure the disease and strategies to reduce the risk of developing it.
Fibromyalgia
1 shared supplement · 49 outcomes
Fibromyalgia is a nonspecific pain disorder with currently unknown causes, although supplements are still being investigated for the purpose of reducing this pain.